Bartholomeus van Rhijn

Bartholomeus van Rhijn, listed as finance chief, appears in our data through filings on Nanobiotix shares, published by AMF. Between 9 December 2024 and 27 June 2025, the trades on record add up to 9 filings.

The open-market record is one-sided, with 8 purchases worth €396k and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 share grant. 2025 to date brings 5 purchases and no sales.

The median purchase comes to €41k. Of 8 purchases, 1 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. For 8 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 88% of cases, with a median move of +50.3%. Past outcomes like these are no guarantee of what comes next.

The latest filing, published on 2 July 2025, reports a share grant of €528k in Nanobiotix. The last purchase on record was published on 28 May 2025, which is 507 days ago. The median gap between a trade and its publication by AMF is 5 days. The regulation allows three business days to notify a trade (MAR article 19). This summary is built from AMF disclosures alone and does not predict where the share price will go.